SX-682
A Phase 1, Open-Label, Dose-Escalation With Expansion Study of SX-682 Alone and in Combination With Oral or Intravenous Decitabine in Subjects With Myelodysplastic Syndrome
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 151 patients (estimated)
- Sponsors
- Syntrix Biosystems, Inc.
- Collaborators
- Moffitt Cancer Center, National Heart, Lung, and Blood Institute (NHLBI), Sidney Kimmel Comprehensive Cancer Center, Winship Cancer Institute, University of Miami, AdventHealth, Mayo Clinic, Montefiore Medical Center
- Tags
- CXCR1 Inhibitor, CXCR2 Inhibitor
- Trial Type
- Treatment
- Last Update
- 4 weeks ago
- SparkCures ID
- 1574
- NCT Identifier
- NCT04245397
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.